Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use

Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use

© 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within t...

Full description

Saved in:
Bibliographic Details
Main Authors: Yohei Sotomi, Pannipa Suwannasom, Erhan Tenekecioglu, Hiroki Tateishi, Mohammad Abdelghani, Patrick W. Serruys, Yoshinobu Onuma
Format: Journal
Published: 2018
Subjects:
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/54803
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-54803
record_format dspace
spelling th-cmuir.6653943832-548032018-09-04T10:23:48Z Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use Yohei Sotomi Pannipa Suwannasom Erhan Tenekecioglu Hiroki Tateishi Mohammad Abdelghani Patrick W. Serruys Yoshinobu Onuma Medicine © 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, neoatherosclerosis, permanent impairment of the physiological vasomotor function and interference with potential future grafting of the stented segment. Bioresorbable scaffolds have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress and mechanotransduction. This article presents a comparison between the most widespread bioresorbable vascular scaffold 'Absorb BVS' and second-generation drug-eluting stent (cobalt chromium everolimus-eluting stent) from bench to clinical use. 2018-09-04T10:23:48Z 2018-09-04T10:23:48Z 2015-01-01 Journal 17448344 14779072 2-s2.0-84942627294 10.1586/14779072.2015.1089172 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/54803
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Yohei Sotomi
Pannipa Suwannasom
Erhan Tenekecioglu
Hiroki Tateishi
Mohammad Abdelghani
Patrick W. Serruys
Yoshinobu Onuma
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
description © 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, neoatherosclerosis, permanent impairment of the physiological vasomotor function and interference with potential future grafting of the stented segment. Bioresorbable scaffolds have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress and mechanotransduction. This article presents a comparison between the most widespread bioresorbable vascular scaffold 'Absorb BVS' and second-generation drug-eluting stent (cobalt chromium everolimus-eluting stent) from bench to clinical use.
format Journal
author Yohei Sotomi
Pannipa Suwannasom
Erhan Tenekecioglu
Hiroki Tateishi
Mohammad Abdelghani
Patrick W. Serruys
Yoshinobu Onuma
author_facet Yohei Sotomi
Pannipa Suwannasom
Erhan Tenekecioglu
Hiroki Tateishi
Mohammad Abdelghani
Patrick W. Serruys
Yoshinobu Onuma
author_sort Yohei Sotomi
title Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_short Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_full Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_fullStr Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_full_unstemmed Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_sort differential aspects between cobalt-chromium everolimus drug-eluting stent and absorb everolimus bioresorbable vascular scaffold: from bench to clinical use
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/54803
_version_ 1681424388055891968

Similar Items